MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial goals ended up To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, although among the list of https://ermaj887dqb2.wikiconverse.com/user